RINVOQ® (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
Active psoriatic arthritis when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated
Manufacturer # 00074230630
Brand RINVOQ®
Manufacturer AbbVie Inc
Country of Origin Ireland
Application Janus Kinase (JAK) Inhibitor
Container Type Bottle
Dosage Form Tablet
Generic Drug Code 46822
Generic Drug Name Upadacitinib
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 00074230630
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Quantity 30 Tablets
Strength 15 mg
Supplier_ID 4384414
Type Extended Release
UNSPSC Code 51386600
